As vaccine makers gear up for a busy season, Seqirus exec says influenza is poised for a return
18 August 2022
As summer nears an end and fall looms, flu season is waiting right around the corner. While much of the public remains focused on the COVID-19 pandemic, influenza remains a threat, and top vaccine players are gearing up to help fight it.
A low-toxic plant-based medicine for type 2 diabetes has been patented in the Russian Federation
18 August 2022
The researchers of the All-Russian Research Institute of Medicinal and Aromatic Plants (FSBRI VILAR) have developed and patented a drug based on elecampane inula, motherwort, lingonberry and rosehip, which reduces blood glucose levels. According to TASS, the drug has high biological activity and low toxicity and is suitable for the treatment of type 2 diabetes and its complications.
Copper coated surfaces found to reduce COVID-19 transmission
17 August 2022
While thin coatings of copper were found to reduce SARS-CoV-2 viral titers on surfaces, silver had a very limited effect.
Does terminal sterilisation affect the quality of ophthalmic APIs?
17 August 2022
EPR summarises research into the impact of gamma irradiation and ethylene oxide sterilisation treatments on European Pharmacopoeial compliance of common ophthalmic APIs.
New screening platform reveals neurodegeneration drug targets in microglia
16 August 2022
As the resident innate immune cells of the brain, microglia are emerging as key drivers of neurological diseases, but as yet there is no systematic way of exploring their potential as drug targets.
Is albumin the key to successful nasal vaccines?
16 August 2022
A new method of mucosal vaccine delivery that uses albumin to help transport vaccine antigens could lead to better vaccines for HIV and COVID-19.
Diabetes brand awareness in the doldrums despite plowing big bucks into ad campaigns
15 August 2022
Diabetes drugs make up one of the biggest selling and most competitive markets in the pharma world. According to market research by Precedence, the global Type 2 diabetes market was just under $30 billion last year. And companies like Novo Nordisk and Eli Lilly are consistently among the highest TV ad spenders for their diabetes meds.
Copper ions speed human tissue regeneration
15 August 2022
An international group of scientists led by a team from Moscow’s MISiS University has developed special copper-coated nanostructured fibrous material that is believed to be able to rapidly release copper ions in a liquid environment.
Band of biotechs cut pipeline prospects to focus cash on priority programs
12 August 2022
Preparing for a prolonged bear market, a raft of biotechs have decided candidates that looked good a few months ago are now an extravagance, leading them to pull back from the programs. Bolt Biotherapeutics, which canned assets to extend its runway into 2025, was one of list of biotechs that have announced pipeline changes since markets closed yesterday.
How does irradiation sterilisation impact herbal medicines?
12 August 2022
EPR discusses the findings of a recent study exploring whether microbicidal treatments using radiation cause the degradation of crude herbal medicinal components.
As vaccine makers gear up for a busy season, Seqirus exec says influenza is poised for a return
18 August 2022
A low-toxic plant-based medicine for type 2 diabetes has been patented in the Russian Federation
18 August 2022
Copper coated surfaces found to reduce COVID-19 transmission
17 August 2022
Does terminal sterilisation affect the quality of ophthalmic APIs?
17 August 2022